---
title: Competition for Cholesterol Players
description: Competition for Cholesterol Players
---

[News ](https://www.yourway.com/news)

# [Competition for Cholesterol Players](https://www.yourway.com/news/competition-for-cholesterol-players)

 Written by [Yourway](https://www.yourway.com/news/author/yourway) | September 30, 2019

The Medicines Company (MDCO) recently [reported](https://endpts.com/franchise-killer-are-regeneron-and-sanofi-about-to-get-handed-their-walking-papers-on-pcsk9/) top-line pivotal data on its siRNA candidate inclisiran, which targets the PCSK9 (proprotein convertase subtilisin/kexin type 9) pathway for lowering cholesterol. According to MDCO, inclisiran reduces levels of LDL cholesterol with just two injections annually. As a premium courier, Yourway functions as the backbone of the supply chain, allowing new therapies to reach patients more efficiently.

[View full post](https://www.yourway.com/news/competition-for-cholesterol-players)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Yourway"
  },
  "dateModified" : "2019-09-30T09:00:11.729Z",
  "datePublished" : "2019-09-30T09:00:00Z",
  "headline" : "Competition for Cholesterol Players",
  "image" : {
    "@type" : "ImageObject",
    "height" : 3500,
    "url" : "https://cdn2.hubspot.net/hubfs/5402331/iStock-1053427712.jpg",
    "width" : 6000
  },
  "mainEntityOfPage" : "https://www.yourway.com/news/competition-for-cholesterol-players",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News"
  }
}
```